JP2018521028A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521028A5 JP2018521028A5 JP2017563997A JP2017563997A JP2018521028A5 JP 2018521028 A5 JP2018521028 A5 JP 2018521028A5 JP 2017563997 A JP2017563997 A JP 2017563997A JP 2017563997 A JP2017563997 A JP 2017563997A JP 2018521028 A5 JP2018521028 A5 JP 2018521028A5
- Authority
- JP
- Japan
- Prior art keywords
- hydro
- pharmaceutical composition
- pharmaceutically acceptable
- peptides
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 25
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 12
- 229960005486 vaccine Drugs 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 208000035269 cancer or benign tumor Diseases 0.000 claims 8
- 239000002671 adjuvant Substances 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 4
- 239000012648 POLY-ICLC Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 239000002955 immunomodulating agent Substances 0.000 claims 4
- 229940121354 immunomodulator Drugs 0.000 claims 4
- 229940115270 poly iclc Drugs 0.000 claims 4
- 229950010550 resiquimod Drugs 0.000 claims 4
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 claims 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 4
- 230000002163 immunogen Effects 0.000 claims 3
- 108700002563 poly ICLC Proteins 0.000 claims 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims 2
- 241000272478 Aquila Species 0.000 claims 2
- 229920002498 Beta-glucan Polymers 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- GUVMFDICMFQHSZ-UHFFFAOYSA-N N-(1-aminoethenyl)-1-[4-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[hydroxy-[[3-[hydroxy-[[3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-[[hydroxy-[2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylimidazole-4-carboxamide Chemical compound CC1=C(C(=O)NC(N)=C)N=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)CO)C(OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)O)C1 GUVMFDICMFQHSZ-UHFFFAOYSA-N 0.000 claims 2
- 108010084333 N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 108010017271 denileukin diftitox Proteins 0.000 claims 2
- 239000008121 dextrose Substances 0.000 claims 2
- 229940056913 eftilagimod alfa Drugs 0.000 claims 2
- 229960002751 imiquimod Drugs 0.000 claims 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 238000002649 immunization Methods 0.000 claims 2
- 230000002584 immunomodulator Effects 0.000 claims 2
- 239000011859 microparticle Substances 0.000 claims 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims 2
- 229940100027 ontak Drugs 0.000 claims 2
- 239000003002 pH adjusting agent Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 2
- 239000001384 succinic acid Substances 0.000 claims 2
- 238000002255 vaccination Methods 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 239000000277 virosome Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000013256 coordination polymer Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 229940074404 sodium succinate Drugs 0.000 claims 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- -1 tricarboxylic acid salt Chemical class 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021102495A JP2021152053A (ja) | 2015-06-09 | 2021-06-21 | 新生物ワクチン用の製剤及びその製剤を調製する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562172890P | 2015-06-09 | 2015-06-09 | |
| US62/172,890 | 2015-06-09 | ||
| PCT/US2016/036605 WO2016201049A2 (en) | 2015-06-09 | 2016-06-09 | Formulations for neoplasia vaccines and methods of preparing thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021102495A Division JP2021152053A (ja) | 2015-06-09 | 2021-06-21 | 新生物ワクチン用の製剤及びその製剤を調製する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018521028A JP2018521028A (ja) | 2018-08-02 |
| JP2018521028A5 true JP2018521028A5 (enExample) | 2019-07-11 |
Family
ID=56236097
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563997A Pending JP2018521028A (ja) | 2015-06-09 | 2016-06-09 | 新生物ワクチン用の製剤及びその製剤を調製する方法 |
| JP2021102495A Pending JP2021152053A (ja) | 2015-06-09 | 2021-06-21 | 新生物ワクチン用の製剤及びその製剤を調製する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021102495A Pending JP2021152053A (ja) | 2015-06-09 | 2021-06-21 | 新生物ワクチン用の製剤及びその製剤を調製する方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20190060428A1 (enExample) |
| EP (1) | EP3307303A2 (enExample) |
| JP (2) | JP2018521028A (enExample) |
| KR (1) | KR20180016531A (enExample) |
| CN (1) | CN107921107A (enExample) |
| AU (1) | AU2016276704A1 (enExample) |
| CA (1) | CA2988135A1 (enExample) |
| CL (2) | CL2017003151A1 (enExample) |
| CO (1) | CO2017012893A2 (enExample) |
| CR (1) | CR20180015A (enExample) |
| EC (1) | ECSP18001613A (enExample) |
| HK (2) | HK1253271A1 (enExample) |
| IL (1) | IL256173A (enExample) |
| MX (1) | MX2017015881A (enExample) |
| PE (1) | PE20180601A1 (enExample) |
| PH (1) | PH12017502233A1 (enExample) |
| RU (2) | RU2753246C2 (enExample) |
| TW (2) | TWI750122B (enExample) |
| WO (1) | WO2016201049A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105648056A (zh) | 2010-05-14 | 2016-06-08 | 综合医院公司 | 鉴定肿瘤特异性新抗原的组合物和方法 |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| EP3082853A2 (en) | 2013-12-20 | 2016-10-26 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| EP3234130B1 (en) | 2014-12-19 | 2020-11-25 | The Broad Institute, Inc. | Methods for profiling the t-cell- receptor repertoire |
| US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
| MX2017014700A (es) | 2015-05-20 | 2018-08-15 | Broad Inst Inc | Neoantigenos compartidos. |
| US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| SG11201912429RA (en) * | 2017-06-21 | 2020-01-30 | Transgene Sa | Personalized vaccine |
| AU2018350891B9 (en) | 2017-10-16 | 2022-05-19 | Illumina, Inc. | Deep learning-based techniques for training deep convolutional neural networks |
| US11861491B2 (en) | 2017-10-16 | 2024-01-02 | Illumina, Inc. | Deep learning-based pathogenicity classifier for promoter single nucleotide variants (pSNVs) |
| WO2019204663A1 (en) * | 2018-04-19 | 2019-10-24 | Neon Therapeutics, Inc. | Peptide formulations and uses thereof |
| US20220349010A1 (en) | 2018-07-26 | 2022-11-03 | Frame Pharmaceuticals B.V. | Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database |
| US20220062394A1 (en) | 2018-12-17 | 2022-03-03 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| JP7665205B2 (ja) * | 2019-03-11 | 2025-04-21 | エヴァクシオン・バイオテック・アクティエセルスカブ | ネオエピトープをコードするコンストラクトを用いた核酸ワクチン接種 |
| CN110514845B (zh) * | 2019-08-22 | 2022-09-27 | 深圳新合睿恩生物医疗科技有限公司 | 一种肿瘤新生抗原免疫原性检测方法及检测平台 |
| KR20220103096A (ko) * | 2019-10-03 | 2022-07-21 | 비트루비아 홀딩스 인코포레이티드 | 결합 조직 복원 방법 |
| GB202104715D0 (en) | 2021-04-01 | 2021-05-19 | Achilles Therapeutics Uk Ltd | Identification of clonal neoantigens and uses thereof |
| CN113461805B (zh) * | 2021-09-02 | 2021-12-10 | 广州吉妮欧生物科技有限公司 | 一种嵌入抗原表位肽的荧光素酶及其构建方法和应用 |
| EP4598949A1 (en) | 2022-10-07 | 2025-08-13 | The General Hospital Corporation | Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins |
| WO2025081106A2 (en) * | 2023-10-12 | 2025-04-17 | Vanderbilt University | Nanobody vaccine compositions |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
| US7767449B1 (en) | 1981-12-24 | 2010-08-03 | Health Research Incorporated | Methods using modified vaccinia virus |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4844893A (en) | 1986-10-07 | 1989-07-04 | Scripps Clinic And Research Foundation | EX vivo effector cell activation for target cell killing |
| CA2005291C (en) | 1988-12-30 | 1999-01-26 | Beverly Dale | Feline infectious peritonitis virus diagnostic tools |
| US6780407B1 (en) | 1989-03-08 | 2004-08-24 | Aventis Pasteur | Pox virus comprising DNA sequences encoding CEA and B7 antigen |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| CA2044593C (en) | 1989-11-03 | 2004-04-20 | Kenneth L. Brigham | Method of in vivo delivery of functioning foreign genes |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5204253A (en) | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
| US5756102A (en) | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
| US6309647B1 (en) | 1999-07-15 | 2001-10-30 | Aventis Pasteur | Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants |
| US6277558B1 (en) | 1990-11-30 | 2001-08-21 | Kansas University Medical Center | α-3 chain type IV collagen polynucleotides |
| AU1588092A (en) | 1991-02-22 | 1992-09-15 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Transmission blocking vaccine against malaria |
| DE69233158T2 (de) | 1991-03-07 | 2004-05-13 | Connaught Technology Corp., Greenville | Gentechnologisch hergestellter stamm für impfstoffe |
| US5766597A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Malaria recombinant poxviruses |
| US5756101A (en) | 1991-07-01 | 1998-05-26 | Pasteur Merieux Serums Et Vaccins | Malaria recombinant poxvirus |
| AU4528493A (en) | 1992-06-04 | 1994-01-04 | Regents Of The University Of California, The | In vivo gene therapy with intron-free sequence of interest |
| DK0758397T3 (da) | 1994-04-29 | 2005-10-10 | Baxter Healthcare Sa | Rekombinante poxvira med fremmede polynucleotider i essentielle regioner |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US6924128B2 (en) | 1994-12-06 | 2005-08-02 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
| US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
| US5849303A (en) | 1995-06-07 | 1998-12-15 | American Home Products Corporation | Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection |
| US5820869A (en) | 1995-06-07 | 1998-10-13 | American Home Products Corporation | Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| FR2750865B1 (fr) | 1996-06-27 | 1998-12-04 | Rhone Merieux | Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2 |
| US6090393A (en) | 1996-07-03 | 2000-07-18 | Merial | Recombinant canine adenoviruses, method for making and uses thereof |
| US6156567A (en) | 1996-07-03 | 2000-12-05 | Merial | Truncated transcriptionally active cytomegalovirus promoters |
| FR2751227B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives |
| US7198784B2 (en) | 1996-10-17 | 2007-04-03 | Oxford Biomedica (Uk) Limited | Retroviral vectors |
| JP4418536B2 (ja) | 1996-10-17 | 2010-02-17 | オックスフォード バイオメディカ（ユーケー）リミテッド | レトロウイルスベクター |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US5990091A (en) | 1997-03-12 | 1999-11-23 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
| US6004777A (en) | 1997-03-12 | 1999-12-21 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
| WO1999015685A1 (en) | 1997-09-19 | 1999-04-01 | The Trustees Of The University Of Pennsylvania | Methods and cell line useful for production of recombinant adeno-associated viruses |
| US6346415B1 (en) | 1997-10-21 | 2002-02-12 | Targeted Genetics Corporation | Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US6953690B1 (en) | 1998-03-20 | 2005-10-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| ATE454445T1 (de) | 1998-11-10 | 2010-01-15 | Univ North Carolina | Virusvektoren und verfahren für ihre herstellung und verabreichung. |
| US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| US6893865B1 (en) | 1999-04-28 | 2005-05-17 | Targeted Genetics Corporation | Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US6793926B1 (en) | 1999-05-27 | 2004-09-21 | Genovo, Inc. | Methods for production of a recombinant adeno-associated virus |
| DE60040147D1 (de) | 1999-05-28 | 2008-10-16 | Targeted Genetics Corp | Methoden und zusammensetzungen zur reduktion des tumor-nekrosis-faktor-spiegels (tnf) bei tnf-assoziierten erkrankungen |
| US7115391B1 (en) | 1999-10-01 | 2006-10-03 | Genovo, Inc. | Production of recombinant AAV using adenovirus comprising AAV rep/cap genes |
| IL150736A0 (en) | 2000-03-14 | 2003-02-12 | Mayr Anton | Altered strain of the modified vaccinia virus ankara (mva) |
| DK1335987T4 (en) | 2000-11-23 | 2016-09-19 | Bavarian Nordic As | Modified variant of vaccinia virus Ankara |
| US7097842B2 (en) | 2000-11-23 | 2006-08-29 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US7628980B2 (en) | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US7445924B2 (en) | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
| US20030104008A1 (en) | 2001-04-06 | 2003-06-05 | Loosmore Sheena May | Recombinant vaccine against west nile virus |
| PL220781B1 (pl) | 2002-04-19 | 2016-01-29 | Bavarian Nordic As | Zastosowanie wirusa krowianki Ankara (MVA) szczepu MVA-BN |
| CA2533581C (en) | 2003-07-24 | 2012-05-08 | Merial Limited | Vaccine formulations comprising an oil-in-water emulsion |
| RU2285548C2 (ru) * | 2004-10-25 | 2006-10-20 | Георгий Цыренович Дамбаев | Способ лечения онкозаболеваний |
| TR201909609T4 (tr) | 2005-08-23 | 2019-07-22 | Univ Pennsylvania | Modifiye edilmiş nükleosidleri içeren rna ve kullanım yöntemleri. |
| EP2131857B1 (en) * | 2007-03-22 | 2015-07-29 | The Regents of the University of Colorado, a body corporate | Method of preparing an immunologically-active adjuvant-bound dried vaccine composition |
| WO2009088786A1 (en) | 2007-12-31 | 2009-07-16 | Nanocor Therapeutics, Inc. | Rna interference for the treatment of heart failure |
| CN105648056A (zh) * | 2010-05-14 | 2016-06-08 | 综合医院公司 | 鉴定肿瘤特异性新抗原的组合物和方法 |
| US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
| GB201022147D0 (en) * | 2010-12-31 | 2011-02-16 | Immune Targeting Systems Its Ltd | Formulation |
| RS64230B1 (sr) * | 2011-05-24 | 2023-06-30 | BioNTech SE | Individualizovane vakcine protiv kancera |
| CA3137846A1 (en) * | 2013-04-07 | 2014-10-16 | The Broad Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
| US20160310584A1 (en) * | 2013-12-06 | 2016-10-27 | The Broad Institute Inc. | Formulations for neoplasia vaccines |
-
2016
- 2016-06-08 TW TW105118230A patent/TWI750122B/zh not_active IP Right Cessation
- 2016-06-08 TW TW110144265A patent/TW202241500A/zh unknown
- 2016-06-09 HK HK18112560.5A patent/HK1253271A1/zh unknown
- 2016-06-09 EP EP16732412.8A patent/EP3307303A2/en not_active Withdrawn
- 2016-06-09 RU RU2017145963A patent/RU2753246C2/ru active
- 2016-06-09 CA CA2988135A patent/CA2988135A1/en not_active Abandoned
- 2016-06-09 RU RU2021122284A patent/RU2021122284A/ru unknown
- 2016-06-09 CR CR20180015A patent/CR20180015A/es unknown
- 2016-06-09 KR KR1020187000589A patent/KR20180016531A/ko not_active Ceased
- 2016-06-09 AU AU2016276704A patent/AU2016276704A1/en not_active Abandoned
- 2016-06-09 PE PE2017002536A patent/PE20180601A1/es unknown
- 2016-06-09 MX MX2017015881A patent/MX2017015881A/es unknown
- 2016-06-09 CN CN201680044845.8A patent/CN107921107A/zh active Pending
- 2016-06-09 HK HK18111607.2A patent/HK1252325A1/zh unknown
- 2016-06-09 JP JP2017563997A patent/JP2018521028A/ja active Pending
- 2016-06-09 WO PCT/US2016/036605 patent/WO2016201049A2/en not_active Ceased
- 2016-06-09 US US15/735,566 patent/US20190060428A1/en not_active Abandoned
-
2017
- 2017-12-07 PH PH12017502233A patent/PH12017502233A1/en unknown
- 2017-12-07 CL CL2017003151A patent/CL2017003151A1/es unknown
- 2017-12-07 IL IL256173A patent/IL256173A/en unknown
- 2017-12-15 CO CONC2017/0012893A patent/CO2017012893A2/es unknown
-
2018
- 2018-01-09 EC ECIEPI20181613A patent/ECSP18001613A/es unknown
-
2019
- 2019-11-14 CL CL2019003264A patent/CL2019003264A1/es unknown
-
2021
- 2021-06-21 JP JP2021102495A patent/JP2021152053A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018521028A5 (enExample) | ||
| RU2021122284A (ru) | Составы вакцин против неоплазии и способы их получения | |
| JP5771626B2 (ja) | 鼻内送達のための方法および組成物 | |
| CA2695399C (en) | Multimeric multiepitope influenza vaccines | |
| JP6792452B2 (ja) | 免疫原性化合物 | |
| Bramwell et al. | Particulate delivery systems for vaccines | |
| WO2017047089A1 (en) | Vaccine compositions | |
| JP2014508734A5 (enExample) | ||
| Khademi et al. | A novel antigen of Mycobacterium tuberculosis and MPLA adjuvant co-entrapped into PLGA: DDA hybrid nanoparticles stimulates mucosal and systemic immunity | |
| JP2018500322A5 (enExample) | ||
| Simerska et al. | Oral vaccine delivery-new strategies and technologies | |
| MX2016003783A (es) | Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv), en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante, apta para su uso farmaceutico. | |
| CN107708730A (zh) | 针对猪流感病毒的基于纳米粒子的疫苗策略 | |
| CA2828068C (en) | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines | |
| JP2017509713A5 (enExample) | ||
| US20180311340A1 (en) | New adjuvant and vaccine composition containing the same | |
| Hojatizade et al. | DDA/TDB liposomes containing soluble Leishmania major antigens induced a mixed Th1/Th2 immune response in BALB/c mice. | |
| US20140322272A1 (en) | Vaccine | |
| Noe et al. | Enabling vaccine delivery platforms and adjuvants for malaria | |
| Dong et al. | pter 4 | |
| Beg et al. | Novel nanocolloidal carriers for noninvasive vaccine delivery | |
| Barnier-Quer | Adjuvanted nanoparticulate seasonal influenza vaccines | |
| HK1192455A (en) | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |